Articles related to DEPRESSION

Discover the implications of a newly identified depression subtype, “cognitive biotype,” which not only presents with significant cognitive impairments but also shows resistance to standard antidepressant treatments.

Discover the advancements in MDD pharmacotherapy that promise to expand treatment options and address unmet needs.

With a focus on evidence-based best practices, this activity will equip you with the tools to translate screening scores, confidently switch between therapies, and differentiate between alternative treatment options.

Explore the intricate landscape of depression, from its genetic underpinnings to innovative treatment approaches. This guide offers physicians a comprehensive overview, aiding in the diagnosis, treatment, and prevention of this pervasive mood disorder.

The FDA’s approval of Zurzuvae (zuranolone) as the first oral treatment for postpartum depression represents a significant advancement in patient care. Physicians are encouraged to explore this new option, considering both its proven efficacy and accompanying warnings, to provide more accessible care for those struggling with this serious condition.

A recent study on bipolar I depression patients found that extended antidepressant maintenance for 52 weeks did not significantly prevent mood episode relapses compared to an 8-week regimen.